Biocytogen and LiberoThera reach landmark in development of Fully Human GPCR Antibody Drugs

US based Biocytogen Pharmaceuticals entered a strategic collaboration with Japan headquartered LiberoThera to co-develop fully human GPCR antibodies using Biocytogen’s advanced antibody discovery platform based on fully human antibody RenMab mice combined with LiberoThera’s outstanding membrane antigen preparation technology. In around a year since the collaboration was established, the two parties have reportedly screened out a […]